LINE-1 METHYLATION IN BLOOD AND TISSUES OF PATIENTS WITH BREAST CANCER.

Published on Mar 1, 2018in Georgian medical news
Ketevani Kankava3
Estimated H-index: 3
(Tbilisi State Medical University),
Kvaratskhelia E3
Estimated H-index: 3
+ 3 AuthorsE. Abzianidze4
Estimated H-index: 4
Source
Abstract
Methylation is an epigenetic alteration proved to be involved in many disease processes including cancer. This change affects mainly gene promoters and repetitive sequences in genome. Long Interspersed Nuclear Element-1 (LINE-1) is a family of retrotransposons - repetitive elements that modify gene activity and can themselves be targeted by epigenetic mechanisms. LINE-1 methylation level is a surrogate marker for global methylation. In many conditions this parameter is found to be altered not only in affected cell groups, but also throughout other tissues. The aim of our study was to compare LINE-1 methylation pattern in DNA extracted from blood of the patients with benign and malignant breast tissue. In addition, we investigated correlation of LINE-1 methylation in blood and tissues of same patients and relationship of all variables with histopathologic and phenotypic characteristics of tumors. Patients with biopsy-proved ductal invasive carcinoma of breast and no preoperative chemo/radiotherapy were chosen for the study group. Another pool of patients with various benign breast lesions represented controls. Blood samples from both group members were collected preoperatively. Tumor tissue sections were processed for pathology report and part of remaining tissue was used for methylation study. LINE-1 methylation level was quantified using ELISA-based assay. It was analyzed in combination with histologic and phenotypic tumor parameters and compared between different tissues and different study groups. LINE-1 was found to be significantly hypomethylated in breast cancer tissue compared to blood. Blood samples of patients with malignant tumors showed slightly lower methylation level, than samples obtained from control group members. Lymphovascular invasion was the only aggressiveness-determining factor that was found to be at least weakly correlated with LINE-1 hypomethylation in blood. We can conclude, that global hypomethylation measured by LINE-1 methylation level is significant in tumor tissue. But there is no significant difference between LINE-1 methylation levels in blood of patients with benign and malignant breast tumors; therefor LINE-1 hypomethylation in blood cannot be used as a marker for early tumor detection. Neither is it valid for determination of tumor behavior.
ūüďĖ Papers frequently viewed together
References0
Newest
Cited By3
Newest
#1Zainab Awada (IARC: International Agency for Research on Cancer)H-Index: 4
#2Liacine Bouaoun (IARC: International Agency for Research on Cancer)H-Index: 8
Last. Akram Ghantous (IARC: International Agency for Research on Cancer)H-Index: 23
view all 11 authors...
Abstract Introduction Lebanon is among the top countries worldwide in combined incidence and mortality of breast cancer, which raises concern about risk factors peculiar to this country. The underlying molecular mechanisms of breast cancer require elucidation, particularly epigenetics, which is recognized as a molecular sensor to environmental exposures. Purpose We aim to explore whether DNA methylation levels of AHRR (marker of cigarette smoking), SLC1A5 and TXLNA (markers of alcohol consumptio...
Source
#1Hitoshi Dejima (University of Texas MD Anderson Cancer Center)H-Index: 4
#2Xin Hu (University of Texas MD Anderson Cancer Center)H-Index: 15
Last. Luisa M. Solis (University of Texas MD Anderson Cancer Center)H-Index: 24
view all 38 authors...
The mechanism by which anti-cancer immunity shapes early carcinogenesis of lung adenocarcinoma (ADC) is unknown. In this study, we characterize the immune contexture of invasive lung ADC and its precursors by transcriptomic immune profiling, T cell receptor (TCR) sequencing and multiplex immunofluorescence (mIF). Our results demonstrate that anti-tumor immunity evolved as a continuum from lung preneoplasia, to preinvasive ADC, minimally-invasive ADC and frankly invasive lung ADC with a gradually...
Source
#37Jianjun Zhang (University of Texas MD Anderson Cancer Center)H-Index: 30
The evolution of anti-tumor immune surveillance during initiation and progression of preneoplasia into invasive lung adenocarcinoma (ADC) and its underlying molecular changes are largely unknown. To fill this void, we characterized the immune contexture of invasive lung ADC (n=12) and its precursors of consecutive developmental stages including preneoplasia atypical adenomatous hyperplasia (AAH, n=22), adenocarcinoma in situ (AIS, n=16), minimally invasive adenocarcinoma (MIA, n=28) as well as p...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.